Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-27
2007-03-27
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000
Reexamination Certificate
active
11244776
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
Bing, H.; S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human Cells; Mol. Cell. Biol.; 2001; 21(8); 2755-2766. Exhibit V, Iddb3 the database on investigational drugs (Jun. 1, 2205 update), Alvocidib.
van del Heuvel, S.; Distinct Roles for Cyclin Dependent Kinases in Cell Cycle Control; Science; 1991; 262, 2050-2053. Exhibit VI, Iddb3 the database on investigational drugs (Jun. 1, 2005 update), Seliciclib. Fischer, P.M.; CDK inhibitors in clinical development for the treatment of cancer; Expert Opin. Investig. Drugs; 2003; 12(6); 955-970.
Byrd, J.; Treatment of Relapsed Chronic Lymphocuic Leukemia by 72-Hour continuous Infusion orl-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B mudy19805; Clin. Cancer. Res.; 2005, 11(11), 4176-4181.
Brwon, J.; Chronic Lymphocytic Leukemia: A Niche for Flavopiridol?;Clin. Cancer. Res.; 2005, 11(11), 3971-3973. Exhibit VII, Iddb3 the database on investigational drugs (Jun. 1, 2205 update), SNS-032.
Dwyer Michael P.
Guzi Timothy J.
Paruch Kamil
Berch Mark L.
Kalyanaraman Palaiyur S.
Moore Susanna
Schering Corporation
LandOfFree
N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797607